Business context and reporting period
Wave Life Sciences Ltd. is a clinical-stage RNA medicines company developing oligonucleotide therapeutics. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2023. Wave has not generated product sales and depends on collaboration revenue and external financing.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $22.1 million | $0.4 million | $35.0 million | $2.1 million |
| Research and development | $33.3 million | $29.7 million | $64.3 million | $57.2 million |
| General and administrative | $12.3 million | $12.8 million | $24.5 million | $25.2 million |
| Net loss | $21.1 million | $41.3 million | $48.5 million | $79.1 million |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $48.3 million provided | $68.7 million used |
- At June 30, cash and cash equivalents were $173.0 million; restricted cash was $3.7 million. Management expected cash and cash equivalents to fund operations for at least 12 months, subject to assumptions that may prove incorrect.
- Six-month operating cash flow included a $104.3 million increase in deferred revenue, primarily from GSK; it should not be read as cash generation from operations alone.
- Total assets were $230.0 million and total liabilities $273.8 million. Current assets were $184.7 million versus current liabilities of $140.2 million. The filing reports no borrowings; lease liabilities were $35.2 million in total, and operating lease commitments were approximately $42.2 million.
- Accumulated deficit was $1.016 billion. No income tax provision was recorded; no meaningful product gross margin was reported.
Material changes versus the prior comparable period
- Revenue rose substantially, mainly because the GSK collaboration became effective in January 2023. GSK collaboration revenue was approximately $20.8 million for Q2 and $33.1 million for the first half; Takeda contributed $1.3 million and $2.0 million, respectively.
- Operating expenses increased by $3.0 million in Q2 and $6.4 million in the first half, with higher R&D partly offset by lower G&A. Increased program spending included Huntington’s disease, DMD and AATD.
- Net losses narrowed year over year, reflecting higher collaboration revenue and other income, despite increased R&D spending.
- Cash and cash equivalents increased from $88.5 million at December 31, 2022 to $173.0 million at June 30, 2023. The change reflected collaboration cash receipts, the GSK equity investment and other financing, including $34.6 million net proceeds from the GSK share issuance.
- Ordinary shares outstanding rose from 86.9 million at year-end 2022 to 98.6 million at June 30, 2023; 98.98 million were outstanding July 27, 2023.
Outlook, commentary and risks
- Wave expects to continue incurring significant R&D costs and operating losses. It may need additional equity, debt or collaboration financing; such funding may be unavailable or dilute shareholders or constrain operations.
- Wave discontinued WVE-004 development after the FOCUS-C9 study showed biomarker reductions but no clinical-benefit trend at 24 weeks. In July 2023, Takeda terminated the C9 target under its collaboration. Wave expected to recognize the remaining $28.0 million of C9 deferred revenue in Q3 2023.
- Management planned to initiate WVE-N531 Phase 2 dosing in 2023 and deliver data in 2024; submit clinical trial applications for WVE-006 in the second half of 2023; and report further WVE-003 biomarker and safety data in the second half of 2023. These are forward-looking plans, not assured outcomes.
- GSK holds an exclusive global license to WVE-006, with development responsibilities transferring after Wave completes the first clinical study. Wave may receive up to $525 million in development, launch and sales milestones, plus tiered royalties; these payments are contingent, not guaranteed.
- Key risks include clinical and regulatory failure, reliance on collaborators, uncertain future financing, competition, manufacturing and intellectual-property challenges, and market and foreign-exchange exposure. Wave reported no material legal proceedings and said disclosure controls were effective.
Investor facts to verify
- Whether the cash runway remains at least 12 months and how much operating cash flow depends on upfront collaboration payments and deferred-revenue changes.
- Recognition and timing of the expected $28.0 million C9-related revenue in Q3 2023, and the remaining performance obligations under GSK and Takeda agreements.
- Execution and results of the stated WVE-N531, WVE-006 and WVE-003 clinical and regulatory milestones.
- Potential dilution from outstanding shares, share-based awards, pre-funded warrants and future financing needs.
- The status and terms of contingent GSK and Takeda milestones, options, termination rights and any future collaboration funding.